For the enrichment and molecular characterization of circulating tumor cells (CTCs) from whole human blood
AdnaTest OvarianCancer allows molecular characterization of CTCs by combining AdnaTest OvarianCancerSelect with AdnaTest OvarianCancerDetect using the Combination of Combinations Principle (COCP). AdnaTest OvarianCancerSelect is a highly specific immunomagnetic cell-selection system for enriching circulating tumor cells from peripheral blood. AdnaTest OvarianCancerDetect allows sensitive analysis of ovarian cancer-associated gene expression in immunomagnetically enriched tumor cells by reverse transcription and PCR.
AdnaTest OvarianCancer are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
AdnaTest OvarianCancer is a highly specific immunomagnetic cell selection system for enriching circulating tumor cells from peripheral blood and includes a highly sensitive RT-PCR for detecting ovarian cancer-specific mRNA markers.
AdnaTest technology uses an optimized combination of antibodies for cell selection in 5 ml whole blood and a combination of tumor-associated markers for the detection of tumor cells: EpCAM, CA15-3 (Muc1) and presence of Her2 receptors (optional detection of estrogen and progesterone receptors by AdnaTest ER/PR-Detect).
The AdnaTest uses a two-step process (Select and Detect) to generate results within 5 hours (see figures “AdnaTest workflow”). AdnaTest OvarianCancerSelect enables the immunomagnetic enrichment of tumor cells from whole blood via epithelial- and tumor-associated antigens. Antibodies against epithelial- and tumor-associated antigens are conjugated to magnetic beads for labeling of tumor cells. Labeled cells are extracted by a magnetic particle concentrator (AdnaMag-L and AdnaMag-S), lysed and mRNA is then purified from these lysates (see figures “AdnaTest Select – Immunomagnetic cell selection with multiple tumor-associated antibodies labeled to magnetic beads”). In the second step, the isolated mRNA is transcribed into cDNA and can be amplified using multiplex PCR (see figures “AdnaTest Detect – Multiplex PCR of various cancer-associated tumor markers”). AdnaTest OvarianCancerDetect contains Oligo (dT) 25-coated beads for the isolation of mRNA from the lysate of pre-enriched tumor cells. Reverse transcription results in cDNA that can subsequently be used as template for tumor cell detection and characterization by multiplex PCR. Multiplex PCR provides tumor-associated gene expression profiles for a variety of relevant tumor markers to ensure that the selected cells are cancer cells. The PrimerMix OvarianDetect allows the amplification of three tumor associated antigens and one control gene. The PrimerMix ERCC1-Detect amplifies the excision repair cross-complementing 1 gene (ERCC1) and one control gene. The two primer-mixes generate the following fragments:
Importantly, the AdnaTest is an open platform that allows the profiling of additional custom selected mRNA targets for comphrehensive biomarker discovery.
fragment fix placeholder